Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâ€™s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 16/06/2026 +04			5-day change	1st Jan Change
23.50 ^USD	+0.09%		-.--%	+159.10%

06-17	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
06-17	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI

Market Cap	152M 133M 123M 113M 215M 14.48B 218M 1.46B 575M 7.14B 570M 558M 24.53B	P/E 2027 *	-	P/E 2028 *	-
Enterprise Value	129M 113M 104M 95.91M 182M 12.28B 185M 1.24B 487M 6.05B 483M 473M 20.79B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	98.57%	Yield 2027 *	-	Yield 2028 *	-

06-17	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
06-17	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI
06-16	Assertio Holdings, Inc.(NasdaqCM:ASRT) dropped from S&P TMI Index	CI
06-16	Assertio Holdings, Inc.(NasdaqGM:ASRT) dropped from NASDAQ Composite Index	CI
06-16	Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc..	CI
05-13	Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc..	CI
05-13	Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. for approximately $160 million.	CI
05-13	Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash	RE
05-13	Assertio Board Approves $23.50-Per-Share Sale to Zydus Worldwide DMCC	MT
05-13	Zydus to Acquire Assertio for $166.4 Million	DJ
05-09	Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Assertio and Garda mutually agree to delay launch of tender offer	RE
05-05	Assertio and Garda mutually agree to postpone commencement of tender offer	RE

04-09	HC Wainwright Downgrades Assertio Holdings to Neutral From Buy, Adjusts Price Target to $18 From $35	MT
03/07/24	HC Wainwright Initiates Assertio Holdings at Buy With $4 Price Target	MT
12/03/24	Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating	MT
10/05/23	BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating	MT
10/05/23	Lake Street Adjusts Assertio Therapeutics' Price Target to $9 From $8, Keeps Buy Rating	MT

Assertio Holdings Stock

Stocks

ASRT

US04546C3043

Pharmaceuticals

Valuation: Assertio Holdings

Chart: Assertio Holdings

Latest news : Assertio Holdings

Last Transcript: Assertio Holdings

Analysts' recommendations: Assertio Holdings

Press Releases: Assertio Holdings

Quotes and Performance

Course Extremes

Managers and Directors: Assertio Holdings

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

06-17	Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027	BU
05-19	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
05-13	Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash	BU
05-08	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer	BU
05-05	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer	BU

1 day	+0.09%
1 month	+0.13%
3 months	+30.41%
6 months	+155.71%
Current year	+159.10%

1 month	23.48	23.5
Current year	9.11	23.5
1 year	8.61	23.5
3 years	7.71	86.7
5 years	7.71	120.15
10 years	7.71	1,621.19

Director	Title	Age	Since
Ravi Yadavar BRD	Director/Board Member	26	16/06/2026
Punit Patel BRD	Director/Board Member	-	16/06/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-16	Heather Mason	Tender	Chief Executive Officer	-69,691	1.0784%
06-16	Ajay Patel	Tender	Chief Financial Officer	-114,019	1.7644%
06-16	William McKee	Tender	Director	-38,766	0.5999%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ASSERTIO HOLDINGS	+0.09%	-.--%	+126.72%	-69.34%	152M
ELI LILLY AND COMPANY	-2.33%	-2.09%	+49.88%	+170.51%	1,060B
JOHNSON & JOHNSON	-0.82%	-2.30%	+63.79%	+62.00%	619B
ABBVIE INC.	-0.73%	-4.98%	+28.91%	+82.99%	438B
ROCHE HOLDING AG	+0.33%	-1.17%	+31.07%	+27.09%	333B
NOVARTIS AG	-0.02%	-2.85%	+29.15%	+45.24%	282B
ASTRAZENECA PLC	-3.89%	-11.22%	+22.81%	+27.30%	267B
NOVO NORDISK A/S	+0.66%	-1.42%	-26.59%	-37.71%	218B
AMGEN INC.	-0.06%	-2.88%	+23.07%	+62.33%	196B
GILEAD SCIENCES, INC.	-3.72%	-1.10%	+18.41%	+70.56%	161B
Average	-1.05%	-2.89%	+36.72%	+44.10%	357.41B
Weighted average by Cap.	-1.31%	-2.96%	+36.75%	+83.90%

	2027 *	2028 *
Net sales	-	-
Net income	400K 350K 323K 298K 566K 38.15M 575K 3.86M 1.51M 18.79M 1.5M 1.47M 64.61M	-
Net Debt	-	-